AstraZeneca Pays $200M Upfront For Global Rights To Targacept's MDD Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
With achievement of milestones, deal could yield $1.24 billion for Phase IIb antidepressant.
You may also be interested in...
Failure Narrows Odds On Targacept Depression Drug; Hope Rests In Remaining Three Trials
Nicotinic receptor company Targacept and TC-5214 partner AstraZeneca remain committed to a 2H 2012 filing of the drug as adjunct therapy for major depressive disorder.
Phase III Flop Narrows Odds On Targacept Antidepressant, But Three Trials Remain
Nicotinic receptor company Targacept and TC-5214 partner AstraZeneca remain committed to a 2H 2012 filing of the drug as adjunct therapy for major depressive disorder.
MDD Market Snapshot: Depressing Future For Antidepressants
Although a significant portion of the U.S. population – approximately 6.5% or 15 million adults annually – suffers from depression, the antidepressant drug market is on the decline and sales are expected to decrease further over the next two years as two of the largest products on the market, Forest Laboratories’ Lexapro (escitalopram) and Eli Lilly & Co.’s Cymbalta (duloxetine), face patent expirations.